Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Roche ramps up immunotherapy R&DSwiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. more ➔
Adaptimmune downgrades trial design after...Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now. more ➔
Multiple sclerosis diagnosis in early stag...Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS). more ➔
BIO Europe with new record numbers Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering … more ➔
AZ withdraws lung cancer drug from EU lead...After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German … more ➔
Bioregions deliver action plan blueprintWhile DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed … more ➔
Germany lagging behind in stem cell resear...A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their … more ➔
